![]() |
|
|
Vol. 285, Issue 3, 987-994, June 1998
Department of Pharmacology, University of Michigan Medical School,
Ann Arbor, Michigan
Pentosan polysulfate (PPS) is a highly sulfated semisynthetic
polysaccharide possessing a higher negative charge density and degree
of sulfation than heparin. Like other glycosaminoglycans, the
structural and chemical properties of PPS promote binding of the drug
to the endothelium. Glycosaminoglycans, including heparin, inhibit
complement activation independent of an action on the coagulation
system. This ability provides a compelling argument for the
implementation of this class of compounds in experimental models of
cellular injury mediated by complement. The objective of this study was
to examine whether PPS could reduce myocardial injury resulting from
activation of the complement system. We used the rabbit isolated heart
perfused with 4% normal human plasma as a source of complement.
Hemodynamic variables were obtained before addition of PPS (0.03 01 mg/ml) and every 10 min after the addition of human plasma. Compared
with vehicle-treated hearts, left ventricular end-diastolic pressure
was improved at the conclusion of the 60-min protocol in hearts treated
with PPS (58.9 ± 13.6 vs. 15.2 ± 4.8 mm Hg).
Further evidence as to the protective effects of PPS was demonstrated
by decreased creatine kinase release compared with vehicle (86.5 ± 28.5 U/l vs. 631.0 ± 124.8 U/l). An
enzyme-linked immunosorbent assay for the presence of the membrane
attack complex in lymph and tissue samples demonstrated decreased
membrane attack complex formation in PPS-treated hearts, which suggests
inhibition of complement activation. This conclusion was supported
further by the ability of PPS to inhibit complement-mediated red blood
cell lysis in vitro. The results of this study indicate that PPS can reduce tissue injury and preserve organ function that
otherwise would be compromised during activation of the human complement cascade.
This article has been cited by other articles:
![]() |
D. A. Lauver, E. A. Booth, A. J. White, E. Poradosu, and B. R. Lucchesi Sulodexide Attenuates Myocardial Ischemia/Reperfusion Injury and the Deposition of C-Reactive Protein in Areas of Infarction without Affecting Hemostasis J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 794 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I-H. Hsu and W. G. Couser Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors? J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S186 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Couser Complement Inhibitors And Glomerulonephritis: Are We There Yet? J. Am. Soc. Nephrol., March 1, 2003; 14(3): 815 - 818. [Full Text] [PDF] |
||||